Moreover, CNTY-101, an iPSC-derived CAR-NK cell product incorporating a CD19 CAR, secreted IL-15, an epidermal growth factor receptor (EGFR)-truncation safety switch, beta-2 microglobulin (B2M) and class II major histocompatibility complex transactivator (CIITA) KOs, and an HLA-E knockin induced tumor shrinkage, including a durable complete response lasting five months, and tumor microenvironment analyses revealed enhanced adaptive immune activation following the infusion (Patel et al., 2024). The gene discussed is HLA-E; the disease is neoplasm.